Entera Bio Ltd

5DT

Company Profile

  • Business description

    Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.

  • Contact

    Minrav Building - Fifth Floor
    Kiryat Hadassah
    Jerusalem9112002
    ISR

    T: +972 25327151

    E: [email protected]

    https://www.enterabio.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    22

Stocks News & Analysis

stocks

3 ASX opportunities after earnings season

Uncovering key opportunities following February’s results.
stocks

Oracle earnings: Solid execution secures revenue target and mitigates investor concerns

We raise our fair value estimate for Oracle stock.
stocks

US dividend shares are getting a boost from the HALO trade. Can it last?

Both high-dividend stocks and dividend-growth stocks are outperforming amid AI disruption.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,793.401.40-0.02%
CAC 407,935.9724.440.31%
DAX 4023,564.01116.720.50%
Dow JONES (US)46,946.41387.940.83%
FTSE 10010,317.6956.540.55%
HKSE25,834.02368.421.45%
NASDAQ22,374.18268.821.22%
Nikkei 22553,751.1568.46-0.13%
NZX 50 Index13,164.5822.76-0.17%
S&P 5006,699.3867.191.01%
S&P/ASX 2008,583.407.800.09%
SSE Composite Index4,084.7910.66-0.26%

Market Movers